Patients & Visitors
Medical Services
Maps & Parking
Health Library
Health Professionals
Careers
Diabetes: Study using Otelixizumab for Type I Diabetes DEFEND-1 is a clinical study evaluating a new investigational agent called otelixizumab for adults with new onset type 1 diabetes. The study is testing otelixizumab to see if it can reduce the destruction of beta cells that make insulin for the body.
DEFEND-1 is a clinical study evaluating a new investigational agent called otelixizumab for adults with new onset type 1 diabetes. The study is testing otelixizumab to see if it can reduce the destruction of beta cells that make insulin for the body.
Listen Now | Download Podcast (mp3)
RELATED INFORMATION
About This Site | Disclaimer | Privacy | Accessibility | Donations | Site Map171 Ashley Avenue, Charleston, SC 29403 1.843.792.1414 | © 2009 Medical University of South Carolina